CareDx, Inc. is a precision medicine company focused on discovering, developing, and commercializing clinically differentiated, high-value diagnostic solutions for transplant patients.
The company’s flagship product, AlloSure, is a non-invasive blood test that measures donor-derived cell-free DNA, providing insights into organ rejection in kidney transplant recipients. CareDx also offers AlloMap, a blood test for heart transplant patients that helps assess the risk of rejection.
In addition to these products, CareDx provides a suite of other diagnostic tests and services designed to improve the long-term outcomes of transplant patients. The company leverages advanced genomics and informatics technologies to deliver personalized care and support clinicians in making informed decisions.
Key drivers of growth for CareDx include the expansion of its product portfolio, increasing adoption of its tests by healthcare providers, and ongoing research and development efforts to address unmet needs in transplant medicine. With a strong focus on innovation and patient care, CareDx continues to enhance its offerings and support the transplant community, aiming to improve the quality of life and survival rates for transplant recipients.
